SPARC wins USFDA priority review voucher tied to Sezaby approval

SPARC

Sun Pharma Advanced Research Company Ltd. (SPARC) on Tuesday said the US Food and Drug Administration (USFDA) has granted a Rare Pediatric Disease Priority Review Voucher (PRV) linked to the approval of its neonatal seizure therapy Sezaby, giving the drug developer a potentially valuable strategic tool to accelerate future medicines.

PRVs are tradable vouchers issued by the USFDA to incentivize development of treatments for rare pediatric conditions, and can be redeemed to secure a priority review for a separate, future drug application—often shaving months off the review clock for high-value assets.

SPARC said it intends to use the voucher to “further accelerate” its pipeline, signaling it may either deploy the PRV internally for a key program or potentially monetize it depending on strategic needs.

“Receiving this Priority Review Voucher is a significant milestone for SPARC and a testament to our commitment to addressing the urgent, unmet needs of patients,” said Anil Raghavan, CEO of SPARC.

“This award not only recognizes the therapeutic value of Sezaby but also provides SPARC with additional strategic flexibility to accelerate our pipeline development to bring more therapies to patients faster.”

The PRV is associated with Sezaby, which SPARC described as a benzyl alcohol- and propylene glycol–free formulation of phenobarbital sodium powder for injection, approved by the USFDA for the treatment of neonatal seizures—a clinical setting where safety considerations around excipients can be particularly important.

For SPARC, the voucher adds another layer of optionality as it pushes its innovation-led portfolio forward.  Shares of SPARC rose 6 percent and were trading Rs 141.30 on BSE on Tuesday at 10.30 am.